Ernexa Therapeutics (NASDAQ:ERNA) Downgraded by Wall Street Zen to Sell

Wall Street Zen downgraded shares of Ernexa Therapeutics (NASDAQ:ERNA) from a hold rating to a sell rating in a research report released on Saturday.

Other equities research analysts have also recently issued reports about the stock. Zacks Research raised shares of Ernexa Therapeutics to a “hold” rating in a report on Monday, May 11th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ernexa Therapeutics in a report on Friday, July 17th. Finally, Brookline Capital Markets started coverage on Ernexa Therapeutics in a research note on Thursday, May 7th. They issued a “buy” rating and a $30.00 price objective for the company. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $30.00.

Ernexa Therapeutics Stock Performance

Ernexa Therapeutics stock opened at $4.21 on Friday. The company has a market capitalization of $4.93 million, a price-to-earnings ratio of -0.29 and a beta of 2.57. Ernexa Therapeutics has a 1 year low of $3.18 and a 1 year high of $71.50. The company’s 50 day simple moving average is $5.88 and its 200-day simple moving average is $8.85.

Ernexa Therapeutics (NASDAQ:ERNA) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($3.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.30) by ($0.10). Equities analysts expect that Ernexa Therapeutics will post -18.02 earnings per share for the current year.

Institutional Trading of Ernexa Therapeutics

A hedge fund recently bought a new position in Ernexa Therapeutics stock. Susquehanna International Group LLP bought a new stake in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned approximately 0.39% of Ernexa Therapeutics at the end of the most recent reporting period. Institutional investors own 70.55% of the company’s stock.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.